Gerresheimer has Passed the Turning Point

    
    -  Nine-Month Sales (Excluding Technical Plastics) 1.7% Down on Prior
       Year

    -  EBITDA Margin at High Level of 17.2%

    -  As Expected, Third Quarter Marked by Inventory Reductions by Large
       Customers
    
</pre>
<p/>
<p><location>DUSSELDORF</location>, <location>Germany</location>, <chron>Oct. 15</chron> /CNW/ - In the first nine months of the financial year (<chron>December 2008</chron> - August 2009), Gerresheimer AG achieved sales of EUR 744.3m (prior year EUR 783.4m). Excluding the Technical Plastics business which has been sold, sales totaled EUR 714.9m, a reduction of 1.7% compared with the prior year. The corresponding operating margin (adjusted EBITDA) for the first three quarters continued on a high level at 17.9%. In Gerresheimer's key market of pharmaceutics, long-term demand is stable although some pharma customers have continued to reduce their inventory levels. The cosmetics sales which accounts for only 10% of total Group sales remained weak as expected. For the fourth quarter, Gerresheimer expects an increase in demand for pharma packaging and a slight recovery in the cosmetics business. It has accordingly quantified more precisely the outlook for the full financial year 2009. Organic growth in the fourth quarter will be offset by the weak dollar exchange rate. For the full year a small sales decline of between 1.5% and 2.5% and an operating margin (adjusted EBITDA) of around 18.5% are expected.</p>
<p>"The trend in the pharma business continues to be characterized by long-term growth. We are successfully pushing ahead with the consistent orientation of the Gerresheimer Group as a leading global partner for the pharma industry," says <person>Dr. Axel Herberg</person>, CEO of Gerresheimer AG. "Our latest investments - particularly in the growth market of pharma plastics - reflect this."</p>
<p>The importance of the Plastic Systems Division, which grew by over 5% at constant exchange rates during the first three quarters, is also shown by the two recent investments. In <chron>September 2009</chron> Gerresheimer opened a new Research and Development Center for Medical Plastic Systems in the USA and a new Production Center for Plastic Packaging in <location>Spain</location>.</p>
<p>Group sales for the third quarter were as expected down on the prior year level of EUR 268.0m at EUR 242.6m. Excluding Technical Plastics, sales totaled EUR 236.9m, a decline of 5.3% against the prior year level. In the generally stable pharma segment some customers used the summer months to carry out further inventory reductions. In the cosmetics and life science segments, sales fell substantially because of weak demand. Operationally, Gerresheimer performed well in the third quarter. Adjusted EBITDA excluding Technical Plastics came to EUR 41.6m. Thanks to capacity and cost adjustments it was possible to hold the operating margin at the high level of 17.6%.</p>
<p/>
<p>Outlook: the turning point has been passed</p>
<p/>
<p>Thanks to rising demand and falling inventories, slight growth is expected for the pharma business in the fourth quarter. In the cosmetics business a slight improvement in demand is also evident, while in the Life Science Research segment no real recovery is foreseeable. For the financial year 2009, Gerresheimer has quantified more precisely the outlook last given in <chron>July 2009</chron>. For the full financial year the company assumes a slight sales decline of 1.5% to 2.5% and an operating margin (adjusted EBITDA) of around 18.5%. For the full financial year 2009 a total investment volume of around EUR 85 - 90m is expected.</p>
<p>"Thanks to our pharma orientation and very early capacity adjustments and cost reduction measures, our business is stable. We see indications that the turning point has already been passed in the third quarter," Herberg says.</p>
<p/>
<p>About Gerresheimer</p>
<p/>
<p>Gerresheimer employs around 10,000 people in 40 locations in <location>Europe</location>, America and Asia. In the financial year 2008, worldwide sales totaled EUR 1.06bn. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterized by high technical and regulatory barriers.</p>
<p/>
<pre>
    
    Group Key Figures
    (IFRS; End of Q3: August 31; Financial Year end November 30)

    in EUR million       Q3     Q3   Change   Q1-Q3   Q1-Q3  Change  FY 2008
                        2009   2008      %     2009    2008      %

    Net sales          242.6  268.0    -9.5   744.3   783.4    -5.0  1.060.1
    Group net sales
     excluding Technical
     Plastics(1)       236.9  250.2    -5.3   714.9   727.4    -1.7    985.9
    Adjusted EBITDA(2)  42.0   50.3   -16.5   127.8   146.9   -13.0    206.4
    in % of net sales   17.3   18.8            17.2    18.8             19.5
    Adjusted EBITDA(2)
     excluding Technical
     Plastics           41.6  N/A(3)          128.1   N/A(3)           N/A(3)
    in % of net sales   17.6  N/A(3)           17.9   N/A(3)           N/A(3)
    Profit from
     operations (EBIT)  12.9  -10.9            33.9    22.5   +50.7     61.0
    Net income          -4.0  -22.8            -4.2   -14.7              4.5
    Adjusted net
     income(4)           7.9   16.5   -52.1    28.6    44.0   -35.0     61.4
    Earnings per
     share in EUR      -0.11  -0.73           -0.15   -0.53             0.02
    Adjusted earnings
     per share(5)
     in EUR             0.20   0.52   -61.5    0.83    1.34   -38.1     1.83

    ------------------------------------------

    (1) Net sales of the recently divested Technical Plastics business (sold
        with effect from July 1, 2009) include the sales of the Technical
        Plastics tool business and amounted to EUR 74.2m in FY 2008

    (2) Adjusted EBITDA: Earnings before income taxes, financial result,
        amortization of fair value adjustments, extraordinary depreciation,
        depreciation and amortization, restructuring expenses and one-off
        income and expenses

    (3) The adjusted EBITDA of the Technical Plastics business of the
        comparative prior year period is not available due to the fact that
        the divestment was carried out in the course of the financial year
        and is therefore included in the Plastic Systems segment

    (4) Adjusted net income: Consolidated profit before non-cash
        amortization of fair value adjustments, special effects from
        restructuring expenses, extraordinary depreciation, the balance of
        one-off income and expenses (including significant non-cash expenses)
        and the related tax effects

    (5) Adjusted net income after minorities divided by 31.4m shares

    --------------------------------------------
    

For further information: Contact Press: Burkhard Lingenberg, Director Corporate Communication & Marketing, Phone [phone], Fax [phone], e-mail [email protected]; Contact Investor Relations: Anke Linnartz, Director Corporate Investor Relations, Phone [phone], Fax [phone], e-mail [email protected]